Cancer Centers Program Update and
Future Directions
Linda K. Weiss, PhD
Director, Office of Cancer Centers
Cancer Center Administrators Forum
April 5, 2011
[email protected]
FY 2010 Funding, Parent Grant and Special Initiatives
FY 2011 Budget
Organizational Changes
Database, Website, and Centers Report
Miscellaneous Items
Program Announcement 11-005
Cancer Center Support Grant Guidelines: Where Next?
• Geographic Distribution of Cancer Centers
– 66 Centers in 33/50 states and DC
– 40 Comprehensive: 23 states and DC
– 26 Cancer Centers: 17 states: 17 states
CCSG Funding By Application Type, FY2010,
$271,490,840 Total Costs, Parent Grant
1%, $1.5 M
$177.0 M, 65%
$43.2 M, 16%
$50.0 M, 18%
FY 10 Funding for Special Initiatives
• Supplemental Initiatives through OCC: $7.4 M
Ca BIG: 0.8 M
AMC: 1.0 M
CFAR: 1.5 M
NCCCP: 0.8 M
RaPID: 3.0 M
Miscellaneous: 0.6 M
• Additional Supplements
– CTRP (NCI CCCT): 5.2 M
– Core Consolidation (NCRR): 8.0 M
FY 2011 Budget
• Centers Baseline
– Continuing Resolution
now in effect until 4/8
– Centers budget has not
been finalized
– T3/5 funded under NIH
policy at 90%
– T1/2 budget pending
• Anticipated
– Clinical Investigator
Team Leadership
– Clinical Trials Reporting
– CFAR – CC Pilot
Project Awards
– AMC – CC Pilot Project
Organizational Changes
• New NCI Leadership
Dr. Harold Varmus, Director
Dr. Douglas Lowy, Deputy Director
Dr. Peter Greenwald, Associate Director for Prevention and Control
John Czajkowski, Deputy Director for Management
Searches underway
Associate Director for Clinical Research
Director Center for Center for Cancer Genomics
Director for Center for Global Health
Director for Division of Cancer Prevention
• Office of Cancer Centers New Staff
– Nga Nguyen, Program Analyst
– Searches underway
• Program Director
• IT Database Specialist
Database, Website and Centers Report
• Summaries
– Send as before to [email protected]
– Send content questions to your program director
• Website Updates
– Send center name, address, directorship changes to your
program director
– More complex changes will be deferred
• Centers Report
– Nearing completion
– Some information will be web-based (e.g., publications,
clinical trials)
Miscellaneous Items
• Include PMCID numbers with publications list
• Large carryover balances are discouraged, particularly
as a repeated pattern; there is no guaranteed approval
• Fewer administrative supplements (extensions with
funds) than in previous years, no ‘recycling’
• New programs and shared resources can’t be
established with CCSG funds during non-competing
years; realigned programs must be approved by staff
Program Announcement 11-005
• Overview Opportunity Announcement
– Effective September 25, 2010, NIH required that all
mechanisms have a Funding Opportunity
Announcement in the NIH Guide for Grants and
– All applications will have to respond to the PAR
– The PAR, new Guidelines, and a comparison of 2008
and 2010 Guidelines are on our website.
Program Announcement 11-005
• Face page of the application must indicate the PAR #
• Resubmission applications (A1) now allowed within 37
• New page limits for components are in effect
• Appendices must be included in the application and
can’t exceed 50 pages
• Late materials must follow NIH policy – much more
stringent limitations
• Submission procedures for letter of approval and
request for preliminary information have changed
Program Announcement 11-005
• Applicants will no longer receive and respond to an
administrative review letter
• Applicants will no longer submit posters and updated
summaries prior to the site visit; information not provided
in the original application can be provided at the site
• The SRO can no longer selectively accept parts of the
• The application can be returned without review if it
doesn’t meet guidelines requirements
Program Announcement 11-005
– The 5 review criteria mandated by NIH (significance,
investigator, innovation, approach and environment) are
now incorporated into the Guidelines.
– The 5 criteria will be incorporated into the evaluation of
overall center impact but not individual components
– Prior to the site visit assigned reviewers will submit
criterion scores for the overall application on the 5 NIH
mandated criteria. These scores will be in the summary
statement, but won’t be discussed at the review.
– The 6th year of funding for centers scoring in the
outstanding range has been eliminated.
– NIH policy and document citations have been updated.
The CCSG Guidelines: Where Next?
• Major Objectives
Foster collaboration and integration
Facilitate clinical and translational research
Reduce the burden of the application process
Provide new guidance on eligibility and budget requests
The CCSG Guidelines: Where Next?
• Foster Collaboration and Integration
– Recognize research collaborations that extend beyond
the walls of the center, including ‘hand-offs’ to other
mechanisms or entities that move scientific findings
– Encourage productive interactions with other NCI and
NIH programs
– Allow sharing of core services across centers
– Eliminate the benchmark ratio
The CCSG Guidelines: Where Next?
• Facilitate Clinical and Translational Research
– Make Clinical Trial and Data Management (the CTO) a
separate component and broaden options for support
– Harmonize guidelines to recognize leadership and
participation in the cooperative groups
– Recognize variety and quality in clinical and translational
– Promote team contributions in clinical research
The CCSG Guidelines: Where Next?
• Reduce the Burden of the Application Process
– Eliminate
• multiple redundancies across components
• detailed capacity and usage tables in shared resource
• data on non-aligned members
• requirements for program meeting agendas
– Streamline
• clinical and other data requirements
• requirements for the administrative component
The CCSG Guidelines: Where Next?
• Provide New Guidance on Eligibility and Budget
– Raise eligibility minimum, e.g., from $4 to $10 M
– Budget Requests
• Base request on percent over prior award or a minimum level or
‘floor’ whichever is greater, e.g.,
– 20% over last T5 award or $2 M DC
• Allow for exceptions, e.g.,
– First T2
– First application after no-cost extension
– Major expansion of research
• Funding level would still be dependent on merit and NCI budget
The CCSG Guidelines: Where Next?
• Other Potential Changes
– More specificity in language for consortium centers
– Expansion/redefinition of staff investigator category
– Modification in criteria for Protocol specific resaerch
– Elimination of the limited site visit
The CCSG Guidelines: Where Next?
• Process
– Collaborators/Consultants
– Review
– Grants Administration
– Senior leadership
• Cancer Centers
– Approvals
• NCI senior leadership
• NCAB Subcommittee on Cancer Centers
• NIH (to include a new PAR)
• Tentative timeline for implementation: 2012

Presentation - Hollings Cancer Center